Zobrazeno 1 - 10
of 221
pro vyhledávání: '"Robert A. Beckman"'
Autor:
Robert A. Beckman
Publikováno v:
npj Systems Biology and Applications, Vol 10, Iss 1, Pp 1-6 (2024)
Abstract A distinct model of neutral evolution of rare cancer mutations is described and contrasted with models relying on the infinite sites approximation (that a specific mutation arises in only one cell at any instant). An explosion of genetic div
Externí odkaz:
https://doaj.org/article/9994bba43f2c44a5a0992c1d0f10ab15
Autor:
Mercedeh Ghadessi, Junrui Di, Chenkun Wang, Kiichiro Toyoizumi, Nan Shao, Chaoqun Mei, Charmaine Demanuele, Rui (Sammi) Tang, Gianna McMillan, Robert A. Beckman
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 18, Iss 1, Pp 1-11 (2023)
Abstract Background Traditional clinical trials require tests and procedures that are administered in centralized clinical research sites, which are beyond the standard of care that patients receive for their rare and chronic diseases. The limited nu
Externí odkaz:
https://doaj.org/article/c2f70ba80edf499990a6da6a4b0a44a2
Autor:
Eric A. Stahlberg, Mohamed Abdel-Rahman, Boris Aguilar, Alireza Asadpoure, Robert A. Beckman, Lynn L. Borkon, Jeffrey N. Bryan, Colleen M. Cebulla, Young Hwan Chang, Ansu Chatterjee, Jun Deng, Sepideh Dolatshahi, Olivier Gevaert, Emily J. Greenspan, Wenrui Hao, Tina Hernandez-Boussard, Pamela R. Jackson, Marieke Kuijjer, Adrian Lee, Paul Macklin, Subha Madhavan, Matthew D. McCoy, Navid Mohammad Mirzaei, Talayeh Razzaghi, Heber L. Rocha, Leili Shahriyari, Ilya Shmulevich, Daniel G. Stover, Yi Sun, Tanveer Syeda-Mahmood, Jinhua Wang, Qi Wang, Ioannis Zervantonakis
Publikováno v:
Frontiers in Digital Health, Vol 4 (2022)
We are rapidly approaching a future in which cancer patient digital twins will reach their potential to predict cancer prevention, diagnosis, and treatment in individual patients. This will be realized based on advances in high performance computing,
Externí odkaz:
https://doaj.org/article/46e800c638964bf3bdfa34d7236e108c
Autor:
Mercedeh Ghadessi, Rui Tang, Joey Zhou, Rong Liu, Chenkun Wang, Kiichiro Toyoizumi, Chaoqun Mei, Lixia Zhang, C. Q. Deng, Robert A. Beckman
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 15, Iss 1, Pp 1-19 (2020)
Abstract Historical controls (HCs) can be used for model parameter estimation at the study design phase, adaptation within a study, or supplementation or replacement of a control arm. Currently on the latter, there is no practical roadmap from design
Externí odkaz:
https://doaj.org/article/fb6cd8f7627f4b48ac3cd4499ca3ba1a
Publikováno v:
Cancer Control, Vol 27 (2020)
Choosing and optimizing treatment strategies for cancer requires capturing its complex dynamics sufficiently well for understanding but without being overwhelmed. Mathematical models are essential to achieve this understanding, and we discuss the cha
Externí odkaz:
https://doaj.org/article/a634a64d506f4619a70c08a85fc63612
Autor:
Jeanne Mendell, Daniel J. Freeman, Wenqin Feng, Thore Hettmann, Matthias Schneider, Sabine Blum, Jens Ruhe, Johannes Bange, Kenji Nakamaru, Shuquan Chen, Zenta Tsuchihashi, Joachim von Pawel, Catherine Copigneaux, Robert A. Beckman
Publikováno v:
EBioMedicine, Vol 2, Iss 3, Pp 264-271 (2015)
Background: During early clinical development, prospective identification of a predictive biomarker and validation of an assay method may not always be feasible. Dichotomizing a continuous biomarker measure to classify responders also leads to challe
Externí odkaz:
https://doaj.org/article/7234004e5d4f47c7ab14202b186df656
Autor:
Li Yan, Robert A. Beckman
Publikováno v:
BioTechniques, Vol 39, Iss 4S, Pp S565-S568 (2005)
Pharmacogenetics and pharmacogenomics are keys to the success of personalized medicine, prescribing drugs based on a patien's individual genetic and biological profile. In this review, we will focus on the application of pharmacogenetics and pharmaco
Externí odkaz:
https://doaj.org/article/eb992401edfd49128f4a96ad57b19d7f
Autor:
A Lawrence Gould, Robert K Campbell, John W Loewy, Robert A Beckman, Jyotirmoy Dey, Anja Schiel, Carl-Fredrik Burman, Joey Zhou, Zoran Antonijevic, Eva R Miller, Rui Tang
Publikováno v:
PLoS ONE, Vol 17, Iss 6, p e0265712 (2022)
The FDA's Accelerated Approval program (AA) is a regulatory program to expedite availability of products to treat serious or life-threatening illnesses that lack effective treatment alternatives. Ideally, all of the many stakeholders such as patients
Externí odkaz:
https://doaj.org/article/df7c2634c3974c088d761e2046bb8771
Publikováno v:
Statistics in Biopharmaceutical Research. :1-9
Publikováno v:
Journal of Biopharmaceutical Statistics. :1-17